Loading clinical trials...
Loading clinical trials...
This study is intended to evaluate treatment effectiveness of BFC compared to FSC in COPD patients new to ICS/LABA combination therapy.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
Collaborators
NCT06847061 · Chronic Obstructive Pulmonary Disease (COPD
NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)
NCT07383896 · Asthma, COPD
NCT07112235 · COPD (Chronic Obstructive Pulmonary Disease), Rhinovirus Infection, and more
NCT07518472 · Pulmonary Disease, Chronic Obstructive (COPD)
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions